Arbutus Biopharma’s (ABUS) “Buy” Rating Reaffirmed at Chardan Capital

Chardan Capital reiterated their buy rating on shares of Arbutus Biopharma (NASDAQ:ABUS) in a research note issued to investors on Wednesday morning, Marketbeat reports. Chardan Capital currently has a $5.00 price target on the biopharmaceutical company’s stock, up from their prior price target of $4.50.

Several other equities research analysts have also recently commented on the stock. Jefferies Financial Group lifted their price target on shares of Arbutus Biopharma from $5.00 to $7.00 and gave the stock a “buy” rating in a research report on Thursday, September 5th. StockNews.com raised shares of Arbutus Biopharma from a “sell” rating to a “hold” rating in a research note on Saturday, August 10th. JMP Securities upped their target price on shares of Arbutus Biopharma to $5.00 and gave the company a “buy” rating in a research report on Wednesday, November 6th. Finally, HC Wainwright restated a “buy” rating and issued a $5.00 price target on shares of Arbutus Biopharma in a research report on Monday, November 18th. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $5.50.

Arbutus Biopharma Stock Up 1.4 %

Arbutus Biopharma stock opened at $3.51 on Wednesday. The business’s 50-day simple moving average is $3.90 and its 200 day simple moving average is $3.64. The stock has a market cap of $665.12 million, a price-to-earnings ratio of -8.12 and a beta of 1.92. Arbutus Biopharma has a 12-month low of $1.79 and a 12-month high of $4.72.

Institutional Investors Weigh In On Arbutus Biopharma

Several large investors have recently bought and sold shares of the company. nVerses Capital LLC bought a new stake in shares of Arbutus Biopharma in the second quarter worth about $34,000. Helen Stephens Group LLC bought a new stake in Arbutus Biopharma during the 3rd quarter worth approximately $50,000. Walleye Trading LLC acquired a new stake in Arbutus Biopharma during the 1st quarter worth approximately $36,000. XTX Topco Ltd bought a new position in Arbutus Biopharma in the second quarter valued at approximately $53,000. Finally, Premier Path Wealth Partners LLC boosted its holdings in shares of Arbutus Biopharma by 18.0% in the second quarter. Premier Path Wealth Partners LLC now owns 36,000 shares of the biopharmaceutical company’s stock valued at $111,000 after buying an additional 5,500 shares during the period. Institutional investors own 43.79% of the company’s stock.

About Arbutus Biopharma

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression.